World Pharma News Digest - 26.10.2009

1 view
Skip to first unread message

Ruslan David

unread,
Oct 26, 2009, 7:11:05 AM10/26/09
to worldph...@googlegroups.com
Advanced Semantic Knowledge-Based Bio-Medical Search Solution 
A web browser that can understand technical terms in life sciences and automatically find additional resources and services has been developed by European researchers. It could lead to a new generation of intelligent search engines. The life sciences community has built numerous databases - such as for gene sequencing and information about diseases - that are available to researchers as 'grid' services. 
Read more... 
http://www.worldpharmanews.com/content/view/992/1/
 
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement 
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced a global licensing agreement on PN2034, a novel oral first-in-class, insulin sensitizer, for the treatment of Type II Diabetes. As a sensitizer, PN2034 is expected to normalize and therefore enhance insulin action in the liver of diabetic patients. The compound is currently in Phase II clinical testing. 
Read more... 
http://www.worldpharmanews.com/content/view/991/1/
 
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer 
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. 
Read more... 
http://www.worldpharmanews.com/content/view/990/1/
 
Bristol-Myers Squibb Achieves Strong Sales 
Bristol-Myers Squibb posted third quarter 2009 net sales from continuing operations of $5.5 billion, an increase of 4%, or 7% excluding foreign exchange impact, compared to the same period in 2008. 
Read more... 
http://www.worldpharmanews.com/content/view/989/1/
 
The 4-T study of intensified insulin regimens shows excellent three-year glucose control 
A long-awaited study presented at the International Diabetes Federation World Diabetes Congress in Montreal, Canada, has shown that it is possible for patients with type 2 diabetes to achieve good blood glucose control with a very low rate of major hypoglycaemia[1] even as they intensify their insulin treatment. 
Read more... 
http://www.worldpharmanews.com/content/view/988/1/
 
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent 
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008. 
Read more... 
http://www.worldpharmanews.com/content/view/987/1/
 
Pfizer Reports Third-Quarter 2009 Results 
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3% compared with $12.0 billion in the year-ago quarter. Revenues for third-quarter 2009 compared with the year-ago quarter were unfavorably impacted by approximately $610 million, or 5%, due to foreign exchange and were favorably impacted by $217 million, or 2%, due to a one-time adjustment in the year-ago period for prior years' liabilities for product returns. 
Read more... 
http://www.worldpharmanews.com/content/view/986/1/
 
Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® 
- Tasigna produced faster and deeper responses compared to Glivec as first-line treatment in Philadelphia chromosome-positive chronic myeloid leukemia
- First registration study using molecular response as key indicator of patient outcomes; Bcr-Abl biomarker test measures very low levels of residual disease[1],[2]
Read more... 
http://www.worldpharmanews.com/content/view/985/1/
 
Abbott Completes Visiogen Acquisition 
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients. 
Read more... 
http://www.worldpharmanews.com/content/view/984/1/
 
FDA approves Cervarix, GlaxoSmithKline's cervical cancer vaccine 
GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25). 
Read more... 
http://www.worldpharmanews.com/content/view/983/1/ 
PharmaNews.eu / Latest News
 
 
Experience of GSK's H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results
http://www.pharmanews.eu/gsk/361-experience-of-gsks-h1n1-adjuvanted-vaccine-pandemrix-and-preliminary-paediatric-results
 
The risk of venous thromboembolism (VTE) associated with oral hormonal contraceptives
http://www.pharmanews.eu/bayer/360-the-risk-of-venous-thromboembolism-vte-associated-with-oral-hormonal-contraceptives
 
Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
http://www.pharmanews.eu/lilly/359-diabetes-conversation-maptm-education-tools-celebrate-one-year-anniversary
 
Results from second clinical trial of GSK's H1N1 adjuvanted vaccine confirm immune response and tolerability
http://www.pharmanews.eu/gsk/358-results-from-second-clinical-trial-of-gsks-h1n1-adjuvanted-vaccine-confirm-immune-response-and-tolerability
 
 
 
AstraZeneca Submits Marketing Authorisation Application to European Union for VIMOVO™
http://www.pharmanews.eu/astrazeneca/355-astrazeneca-submits-marketing-authorisation-application-to-european-union-for-vimovo
 
Pfizer And Wyeth Become One: Working Together For A Healthier World™
http://www.pharmanews.eu/pfizer/354-pfizer-and-wyeth-become-one-working-together-for-a-healthier-world
 
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages